<DOC>
	<DOCNO>NCT02918968</DOCNO>
	<brief_summary>The objective study compare efficacy safety combination therapy enzalutamide + androgen deprivation therapy ( ADT ) combination therapy flutamide + ADT patient castration resistant prostate cancer relapse combined androgen blockade ( CAB ) therapy bicalutamide ADT . This study also investigate order alternative antiandrogen therapy ( AAT ) change 1st line medication relapse prostate-specific antigen ( PSA ) .</brief_summary>
	<brief_title>Study Enzalutamide Flutamide Patients With Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Subject diagnose histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation smallcell histology . Subject continuous ADT Gonadotropin Releasing Hormone ( GnRH ) agonist/antagonist bilateral orchiectomy . Serum testosterone level target level screen visit . Subject asymptomatic mildly symptomatic prostate cancer . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject progression disease define rise PSA level progressive soft tissue bony disease CAB therapy combination bicalutamide ADT . A sexually active male subject subject 's female partner childbearing potential must use 2 acceptable birth control method screen 3 month last dose study drug . Subject must agree donate sperm screen 3 month last dose study drug . Subject severe concurrent disease , infection , complication . Subject confirm suspected brain metastasis active leptomeningeal metastasis . Subject history malignant tumor prostate cancer past 5 year . Subject hypersensitive ingredient enzalutamide capsule flutamide tablet . Subject history convulsive attack , prone convulsive attack . Subject liver disorder viral hepatitis hepatic cirrhosis , subject Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) screen visit high upper limit normal . Subject receive treatment prostate cancer cytocidal chemotherapy include anti androgenic agent bicalutamide , abiraterone , estramustine .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>